Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Intelligent design: combination therapy with oncolytic virusesFrom scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerHigh-throughput screening to enhance oncolytic virus immunotherapyCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesMolecular imaging of oncolytic viral therapyOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesCellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropismIntravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamstersCell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Impact of tumor microenvironment on oncolytic viral therapyCombination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing micePotent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cellsThe combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Current status of gene therapy for brain tumors.Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivoIn vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cellsPhotodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyBevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirusThe Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentAssessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.Oncolytic measles virus strains as novel anticancer agents.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Oncolytic vaccinia virus for the treatment of cancer.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Targeting autophagy to enhance oncolytic virus-based cancer therapy.
P2860
Q24596171-3CEE6994-305F-44B1-8D06-25132EB82576Q24628227-10AC97D2-E9F6-489B-8318-3630ADCD8C28Q26822694-4219C2EC-9420-4B99-A34D-4FC7EF65E372Q26823674-18F1450B-0CFF-4636-A6A9-E48AC20C7416Q26863779-F71A5283-D028-4C08-BDE1-E122E14E7C6FQ26999406-7BE9CEB4-F459-408F-A547-CBDB8F499215Q27007519-A77FA3C3-E58B-492A-AAA3-120067A1D9E4Q30395978-833CC76C-FCA8-450A-ABD9-1A0DD57571CEQ30502129-95575700-4BB2-43EA-9E6B-52883DE71B9DQ33523284-AFB305D7-B450-4251-9651-39B5452465D9Q33580223-4E5D2E1F-AF16-4BB9-A75F-B6DE60D9BBBCQ33601533-88BDC725-8F73-4C01-85CB-F480F08F8F05Q33667768-E00D0104-F954-4BF0-A613-D6A45775AF49Q33768177-5EE391E3-4BBE-4842-A984-EC05787A505AQ33895533-3EC77E9A-1C49-4EEB-8A22-66992E34C363Q33927165-19A220D1-8C95-44F6-9B07-CC847C5C88D1Q33931640-32967343-AFAC-4C79-8DF4-83D70AA64785Q34059205-B8958C5A-DC8D-4963-BCF5-9B2FE8DB5D6CQ34076586-99FB95F1-ED3C-4A28-BE2E-987F59328F2DQ34316241-DFD6748A-0FB8-4194-864E-26BE15EA3301Q34318157-9E97E933-A454-4CEA-B058-8B30489C8FDEQ34343768-92680079-679A-4D68-8D33-E84E20AC2078Q35077031-9102A8C9-2540-4CC9-8772-0777A9FD8919Q35545752-67568BC8-E786-493E-9F86-ECCD06204E69Q35623101-F36235A2-B923-4234-8E4B-AD9B1ECF8112Q35657822-417AAEC1-389C-4938-B61F-7D79DAC46AC8Q35665220-75DC8215-C4CA-473D-8684-828467DC8D49Q36516586-F565B311-B386-4E3C-90C8-EDDAD18E6526Q36642630-21C1F610-A25D-4D11-8B00-FDDA2F2F0DECQ36658280-EC5C56C6-995F-4446-BC99-66B448B95397Q36664268-0F4DC3BA-185B-4711-9016-A8B8B8420703Q37129177-8A8D581E-1F19-4BE3-922B-EA41D04E441BQ37185367-92E3BF2F-C19A-4EA1-93DA-FCE6F5551EADQ37261017-27A217E5-82E6-4E6C-829C-BAF644831F2AQ37561072-50DBB5D6-F014-4E46-9E96-E936BD7EE438Q37564490-5BE80754-C0B4-4606-8D2D-9C95571009B1Q37845399-9309FBDC-750D-4B4A-B3A3-03DB078E9D41Q37899223-5BEF2BCF-87CE-41E5-A99B-1CF18A78C17AQ37933439-B761FDAB-5C21-48FF-B98B-5BCF517F751EQ38089106-6FF92E09-3577-4717-9472-B76A10B0F804
P2860
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@en
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@nl
type
label
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@en
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@nl
prefLabel
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@en
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@nl
P2093
P1476
Efficacy of systemically admin ...... rapamycin or cyclophosphamide.
@en
P2093
Catherine L Nutt
David F Stojdl
Donna L Senger
Helen Deng
J Andrea McCart
Ji-Hyun Jang
Peter A Forsyth
Renee Head
Xue Qing Lun
P304
P356
10.1158/1078-0432.CCR-08-2342
P407
P50
P577
2009-04-07T00:00:00Z